(Reuters) – Drug developer Otonomy Inc said on Thursday its drug to treat acute otitis externa (AOE), an infection in the outer ear canal, met the main goal in a late-stage trial. AOE, also known as swimmer’s ear, is a type of bacterial infection causing inflammation in the external ear canal. Children suffering from middle-ear infection, also known as otitis media with effusion (OME), undergo a tympanostomy tube placement surgery to drain out accumulated fluid and simplify the administration of antibiotics.
Go here to read the rest:
Otonomy’s ear infection drug succeeds in late-stage trial